People

David Snow joined PorTal Access’s board in February 2026 after four decades of pharmaceutical and biotechnology commercial leadership. He led Regeneron’s commercial immunology team until retirement in 2025 and previously served as President of AstraZeneca China. He holds a business-administration degree from Auburn University and an MBA from NYU Stern.